Clinical trials: Acromegaly
Acromegaly
Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
The purpose of this study is to determine whether subjects with acromegaly (or their partners) are able to self administer Somatuline Autogel at home.
- Trial name
- SALSA (NCT00447499)
- Testing
- Somatuline Autogel (lanreotide acetate), Home administration
- Where
- 13 sites in United States
- Volunteers
- 59 people
- Sponsor
- Ipsen
Acromegaly
Long Term Study With B2036-PEG
Primary objective: To investigate the efficacy and safety of Pegvisomant in Japanese patients with acromegaly.
- Trial name
- NCT00143416
- Testing
- Pegvisomant
- Where
- 8 sites in Japan
- Volunteers
- 16 people
- Sponsor
- Pfizer
Acromegaly
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
This study will evaluate the efficacy and safety of pasireotide LAR 40 and 60 mg versus octreotide LAR or lanreotide ATG in patients with inadequately controlled acromegaly.
- Trial name
- PAOLA (NCT01137682)
- Testing
- Pasireotide, octreotide LAR 30mg, lanreotide ATG 120mg
- Where
- 60 sites in United States, Argentina and 16 more
- Volunteers
- 198 people
- Sponsor
- Novartis Pharmaceuticals
Acromegaly
Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly
The purpose of this study is to compare the effectiveness of lanreotide autogel to placebo after a single injection. Effectiveness and safety were then also assessed following four fixed-dose injections and after one year of…
- Trial name
- NCT00234572
- Testing
- Lanreotide (Autogel formulation)
- Where
- 29 sites in United States, Czechia and 6 more
- Volunteers
- 108 people
- Sponsor
- Ipsen
Acromegaly
Single-dose Study to Evaluate the Absolute Bioavailability and Mass Balance of ONO-5788
A phase 1 healthy volunteer study to assess the excretion and metabolism as well as the absolute bioavailability of oral ONO-5788.
- Trial name
- ONO-5788-02 (NCT03849872)
- Testing
- ONO-5788, [14C]-ONO-5788
- Where
- Netherlands
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Acromegaly
Study to Assess the Efficacy and Safety of Repeated Administration of BIM 23A760 in Patients With Acromegaly
The purpose of this study is to assess the efficacy of repeated subcutaneous (under the skin) injections at different doses of BIM 23A760 on growth hormone and insulin-like growth factor-1 levels in patients with acromegaly after…
- Trial name
- TULIPIA (NCT00994214)
- Testing
- BIM 23A760
- Where
- 23 sites in United States, Belgium and 11 more
- Volunteers
- 109 people
- Sponsor
- Ipsen
Acromegaly
Assessment of BIM23B065, Given as Repeated Subcutaneous Injection in Subjects With Acromegaly
The purpose of the protocol is evaluate the safety, the pharmacodynamics and the pharmacokinetic of repeated administration of BIM23B065 in subjects with acromegaly.
- Trial name
- DOPAACRO 002 (NCT03045302)
- Testing
- BIM23B065
- Where
- 6 sites in Belgium, Hungary and 2 more
- Volunteers
- 4 people
- Sponsor
- Ipsen
Acromegaly
Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly
A multicentre, prospective, open label study of acromegalic patients evaluating the efficacy and safety of different dose-intervals of Lanreotide Autogel 120mg according to international standards and compared to previous…
- Trial name
- NCT00444873
- Testing
- lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval
- Where
- Germany
- Volunteers
- 38 people
- Sponsor
- Ipsen
Acromegaly
Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands
The purpose of this study was to assess the safety, tolerability, and efficacy of IONIS-GHR-LRx in up to 60 participants with acromegaly.
- Trial name
- NCT03548415
- Testing
- IONIS-GHR-LRx
- Where
- 33 sites in United States, Hungary and 5 more
- Volunteers
- 43 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Acromegaly
Somatuline Autogel: Acromegaly Self/Partner Injection Study
The purpose of this study is to allow patients with acromegaly, or their partners, to learn how to successfully inject Somatuline Autogel at home.
- Trial name
- NCT00149188
- Testing
- Lanreotide (Autogel formulation)
- Where
- 10 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Ipsen
Acromegaly, Neuroendocrine Tumours
Somatuline Predictive Factors in Acromegaly and NET
The aim of the study is to identify predictive factors for the response to Lanreotide treatment in Acromegaly as well as in Neuroendocrine Tumours.
- Trial name
- SOPRANo (NCT01840449)
- Testing
- Somatuline Autogel® 60, 90 or 120 mg
- Where
- 3 sites in Austria, Germany and 1 more
- Volunteers
- 156 people
- Sponsor
- Ipsen
Acromegaly
A Clinical Trial to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Octreotide Long-acting Injection in Patients With Acromegaly
This trial is a phase II clinical trial to evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of octreotide long-acting injection in patients with acromegaly.
- Trial name
- NCT07814651
- Testing
- SYHX2008, Sandostatin LAR
- Where
- China
- Volunteers
- 78 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Acromegaly
A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)
A phase 2, open label, long-term extension study designed to evaluate the safety and efficacy of paltusotine (formerly CRN00808; an oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with…
- Trial name
- NCT04261712
- Testing
- Paltusotine
- Where
- 22 sites in United States, Brazil and 5 more
- Volunteers
- 43 people
- Sponsor
- Crinetics Pharmaceuticals Inc.
Acromegaly
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
Octreotide capsule is a novel, orally-administered formulation of the commercially-available injectable drug octreotide. In a recent phase 3 trial, oral octreotide capsules demonstrated maintenance of biochemical response up to…
- Trial name
- OPTIMAL (NCT03252353)
- Testing
- octreotide capsules
- Where
- 60 sites in United States, Australia and 15 more
- Volunteers
- 56 people
- Sponsor
- Chiasma, Inc.
Acromegaly
Pegvisomant And Sandostatin LAR Combination Study
The purpose of this study is to compare the safety and tolerability of combination therapy with Sandostatin LAR plus Pegvisomant to that of Sandostatin LAR alone or Pegvisomant alone.
- Trial name
- NCT00068029
- Testing
- Pegvisomant/ Sandostatin LAR, Sandostatin LAR, Pegvisomant
- Where
- 33 sites in United States, Australia and 10 more
- Volunteers
- 75 people
- Sponsor
- Pfizer
Acromegaly
Phase II Study With ITF2984 in Acromegalic Patients
The purpose of this study is to investigate in acromegalic patients the effect of different doses of ITF2984 on GH and IGF-1 concentrations and to investigate safety and tolerability of three different doses of ITF2984.
- Trial name
- POC (NCT02111044)
- Testing
- Octreotide, ITF2984 500 mcg, ITF2984 1000 mcg
- Where
- 26 sites in Czechia, France and 7 more
- Volunteers
- 48 people
- Sponsor
- Italfarmaco
Acromegaly
A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult Volunteers
This is a first in human study to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of ONO-5788 in healthy adult volunteers.
- Trial name
- NCT03571594
- Testing
- ONO-5788, Octreotide
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Acromegaly
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve)
A Phase 2 double-blind, placebo-controlled, randomized withdrawal study is designed to evaluate the safety, efficacy, and pharmacokinetics of paltusotine (formerly CRN00808) in subjects with acromegaly that are responders to…
- Trial name
- NCT03792555
- Testing
- Paltusotine
- Where
- 11 sites in United States, Brazil and 6 more
- Volunteers
- 13 people
- Sponsor
- Crinetics Pharmaceuticals Inc.
Acromegaly
Real-World Study (RWS) of Lanreotide Autogel (LAN) for the Treatment of Patients With Acromegaly in China
This study aims to assess the one-year effectiveness and safety of LAN among patients with acromegaly in China in routine clinical practice.
- Trial name
- NCT05431803
- Where
- 12 sites in China
- Volunteers
- 129 people
- Sponsor
- Ipsen
Gastro-enteropancreatic Neuroendocrine Tumor, Acromegaly
A Study to Understand Participant's Experiences in Gastro-enteropancreatic Neuroendocrine Tumors (GEP-NETs) and Acromegaly
Participants of this study are adults with GEP-NETs and/or acromegaly who were using the Ipsen lanreotide syringe and have transitioned in the last 6 months to the Pharmathen lanreotide syringe, having received at least two…
- Trial name
- BackSOM (NCT06253897)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Ipsen